Med-Life Discoveries

07/24/2025

Dr. Tara Smith laying out the future plans for plasmalogen therapy in RCDP and the RhizoKids International conference

07/24/2025

Shawn Ritchie gave a great presentation this morning at the RhizoKids International conference talking about the basics of plasmalogens and how these special lipids underlie the RCDP disease process.

07/22/2025

MLD is thrilled to be back to Children’s Harbor for Rhizokids International 2025 Family Conference.

06/24/2025

MLD is excited to announce that we are heading to the RhizoKids Conference in July and we want to know what Rhizofamilies would like to hear about from us! Click the link to complete the poll.

Rhizofamilies we are thrilled to announce that MLD will once again be attending the annual RhizoKids Conference this July! Shawn Ritchie, CEO and Chief Scientific Officer, and Tara Smith, Exec. Vice President, will be there throughout the conference and would love to talk to everyone and answer any

05/31/2025

In support of RhizoKids International’s RCDP Awareness Day, MLD would like to help raise awareness and there is no better way to learn about this disease than from the parents of RhizoWarriors. For this reason, we are reposting the Voice of the Patient Report where many RCDP parents describe what the disease is like for their children and the challenges they face.

04/24/2025

MLD in Boston at World Orphan Drug Congress getting the latest insights into orphan drug development and everything rare!

04/17/2025

We wanted share what a 373 kg shipment of packaged PPI-1011 looks like! This photo was taken today in our Canadian GMP drug product manufacturing and packaging facility as the shipment heads to a new location for more safety testing!! Happy Easter Weekend everyone!

04/10/2025

Check out our new post addressing the differences between approved drugs and supplements.

To the RCDP community, we want to address the on-going confusion over the safety and regulatory requirements for developing approved drugs versus "supplements”. Although we have gone in-depth on these differences in the past (see our video on this topic), we wanted to be straight up on the k

03/31/2025

MLD is excited about the publication of the first quality of life survey specific for RCDP, RhizoQOL. A huge thank you goes out to Dr. Mousumi Bose, her team at Montclair State University, the RCDP families involved, and everyone else who helped in the creation of this instrument.

To read the paper, click the link below.

MLD is happy to announce that it has published the first RCDP-specific quality-of-life instrument, RhizoQOL. MLD has been working in collaboration with Dr. Mousumi Bose and her team at Montclair State University to develop a survey that will appropriately capture the quality-of-life of individuals w

03/17/2025

MLD is happy to announce the publication of its successful Phase I trial. For more information see the link below.

RCDP is a rare pediatric disorder caused by mutations in one of the genes in the plasmalogen biosynthetic pathway, resulting in low plasmalogen levels. The plasmalogen deficiency leads to several clinical manifestations causing profound physical and cognitive deficiencies and a significantly reduced...

02/28/2025

This Rare Disease Day we are spreading awareness about RCDP by presenting a poster on the RCDP PFDD meeting that was successfully held last summer. We originally planned to be at the FDA-NIH Rare Disease meeting but when we found out that was postponed, we knew this work still needed to be presented so we headed to Seattle to the Rare Genetic Disease Research in Seattle and Beyond meeting. The response was overwhelming. Both clinician and researchers were very interested in learning about RCDP and how MLD and Rhizokids work together to capture the patients’ voice.

02/28/2025

This Rare Disease Day, MLD is thrilled to support RhizoKids International as they release the official RCDP Voice of the Patient Report. The report is the culmination of RhizoKids International’s Patient-Focused Drug Development session which took place last July. This document is an invaluable resource for educating physicians, other healthcare professionals, drug developers, and the FDA about challenges associated with RCDP and what caregivers are looking for in a treatment for their children.